It is important to adhere to the prescribed dose and not exceed it
This milestone reinforces Eccogenes position as an innovator in advancing novel, differentiated oral therapies for cardiometabolic diseases with broad commercial potential. Sharon Barr, Executive Vice President, BioPharmaceuticals R&D at AstraZeneca, commented: The start of this Phase 1b trial in China marks an important milestone in the extensive clinical program for AZD5004/ECC5004, an oral small molecule GLP-1RA which has significant potential as part of our extensive CVRM portfolio
Consider working with a registered dietitian who can help tailor a meal plan that aligns with your goals and lifestyle
Those who live with T1D and use cannabis have 2 to 3 times higher risk of developing DKA
It is the only treatment to show significant fibrosis regression in compensated #cirrhosis (F4) patients in a Phase 2 trialan area of urgent unmet need
Fibromyalgia Fibromyalgia is a condition where central pain sensitization, rather than peripheral inflammation, drives the symptom picture